Nasdaq · CIK 0001420720
IBIO iBio, Inc.
Insider trading from SEC Form 4. Last filing Nov 24, 2025. Close $0.87 on Oct 9, 2026, +10% from the 52-week low and -72% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
IBIOOct 9, 2026 · close 0.87
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at iBio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | David Arkowitz director buy | $50k 18,382 shares | - | - | |
| 40Moderate | Marc Banjak Chief Legal Officer buy | $25k 9,191 shares | +490% | - | |
| 40Moderate | Martin Brenner See Remarks buy | $25k 9,191 shares | +101% | - | |
| 38Weak | William D Clark director buy | $4,999 1,838 shares | - | - | |
| 47Moderate | Felipe Duran Chief Financial Officer buy | $25k 9,191 shares | +472% | - |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | David Arkowitz director | AGrant or award Stock Option (right to buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Nov 24, 2025 |
| Oct 20, 2025 | Marc Banjak Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Oct 22, 2025 |
| Oct 20, 2025 | Martin Brenner See Remarks | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Oct 22, 2025 |
| Feb 21, 2025 | Marc Banjak Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +71,000 | $0.00 | $0 | 71,000 | Feb 24, 2025 |
| Feb 21, 2025 | Martin Brenner See Remarks | AGrant or award Stock Option (right to buy)derivative | +230,700 | $0.00 | $0 | 230,700 | Feb 24, 2025 |
| Feb 21, 2025 | Felipe Duran Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +84,700 | $0.00 | $0 | 84,700 | Feb 24, 2025 |
| Jan 10, 2025 | Martin Brenner See Remarks | POpen-market purchase Common Stock | +9,191 | $2.72 | $25k | 18,316 | Jan 13, 2025 |
| Jan 10, 2025 | Felipe Duran Chief Financial Officer | POpen-market purchase Common Stock | +9,191 | $2.72 | $25k | 11,139 | Jan 13, 2025 |
| Jan 10, 2025 | William D Clark director | POpen-market purchase Common Stock | +1,838 | $2.72 | $4,999 | 1,838 | Jan 13, 2025 |
| Jan 10, 2025 | Marc Banjak Chief Legal Officer | POpen-market purchase Common Stock | +9,191 | $2.72 | $25k | 11,066 | Jan 13, 2025 |
| Jan 10, 2025 | David Arkowitz director | POpen-market purchase Common Stock | +18,382 | $2.72 | $50k | 18,382 | Jan 13, 2025 |
| Nov 21, 2024 | Antonio Bernardino Guimaraes Parada director | AGrant or award Stock Option (right to buy)derivative | +12,600 | $0.00 | $0 | 12,600 | Dec 9, 2024 |
| Nov 21, 2024 | David Arkowitz director | AGrant or award Stock Option (right to buy)derivative | +12,600 | $0.00 | $0 | 12,600 | Nov 25, 2024 |
| Nov 21, 2024 | William D Clark director | AGrant or award Stock Option (right to buy)derivative | +18,900 | $0.00 | $0 | 18,900 | Nov 25, 2024 |
| Nov 21, 2024 | Alexandra Kropotova director | AGrant or award Stock Option (right to buy)derivative | +18,900 | $0.00 | $0 | 18,900 | Nov 25, 2024 |
| Nov 21, 2024 | Evert B. Schimmelpennink director | AGrant or award Stock Option (right to buy)derivative | +18,900 | $0.00 | $0 | 18,900 | Nov 25, 2024 |
| Nov 21, 2024 | Gary Sender director | AGrant or award Stock Option (right to buy)derivative | +18,900 | $0.00 | $0 | 18,900 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- David Arkowitzdirector
- Marc BanjakChief Legal Officer
- Martin BrennerSee Remarks
- William D Clarkdirector
- Felipe DuranChief Financial Officer
- Alexandra Kropotovadirector, officer
- Antonio Bernardino Guimaraes Paradadirector
- Evert B. Schimmelpenninkdirector, ceo, president, officer
- Gary Senderdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.